Using cutting edge technologies including next generation sequencing of laser capture microdissected formalin-fixed tissue, we are comparing the genomic and transcriptomic profiles of high grade prostate cancers (that have progressed to Gleason score 7 or higher) to indolent cancers (Gleason score 6 prostate cancers from an active surveillance cohort). We are also comparing the genomic trajectory of cancers that respond to systemic therapy to those that fail to respond. We hypothesize that a switch in the early natural history of the tumor sets an aggressive fate that can be detected early, guiding options for management and treatment.
| Sowalsky, Adam G; Ye, Huihui; Bhasin, Manoj et al. (2018) Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res 78:4716-4730 |
| Sowalsky, Adam G; Kissick, Haydn T; Gerrin, Sean J et al. (2017) Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clin Cancer Res 23:3823-3833 |
| VanderWeele, David J; Turkbey, Baris; Sowalsky, Adam G (2016) PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER. Expert Rev Precis Med Drug Dev 1:505-515 |
